SCHEDULE 13G/A: BlackRock Discloses 1.9% Passive Stake in Ventyx Biosciences

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 1.9% passive beneficial ownership stake in Ventyx Biosciences, Inc. as of June 30, 2025.

Summary

• BlackRock, Inc. reported beneficial ownership of 1,350,987 shares of Ventyx Biosciences, Inc. Common Stock.
• This ownership represents 1.9% of the total outstanding class of securities.
• BlackRock holds sole voting power over 1,343,394 shares and sole dispositive power over 1,350,987 shares.
• The filing is an Amendment No. 1 to a Schedule 13G, indicating an update to a previously reported stake.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Ventyx Biosciences, Inc.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While a passive stake below 5% is not inherently strong, BlackRock's continued presence as a shareholder can be viewed as a baseline positive, indicating the company remains on their investment radar.

Positives

• BlackRock's continued holding of a stake in Ventyx Biosciences, Inc. may signal a degree of confidence in the company's long-term prospects from a major institutional investor.

Risks

• The filing explicitly states that BlackRock's stake is passive and not intended to influence or change control of Ventyx Biosciences, Inc., meaning BlackRock will not actively push for strategic changes or governance reforms.

Future Outlook

This filing does not provide forward-looking statements or guidance regarding Ventyx Biosciences, Inc.'s future performance or BlackRock's investment strategy beyond its current passive holding.

Industry Context

BlackRock, as one of the world's largest asset managers, routinely files Schedule 13G reports to disclose its passive ownership stakes in publicly traded companies across various sectors, including biotechnology. This filing reflects a standard portfolio holding within its managed funds.

Stakeholder Impact

• Shareholders: BlackRock's passive stake indicates a lack of intent to influence corporate control, which may reassure existing management and board members regarding stability. It also signals continued institutional interest in the company.
• Management: The filing confirms BlackRock's role as a passive investor, not seeking to influence strategic decisions or management changes.

Key Dates

Keywords

Ventyx Biosciences, BlackRock, Schedule 13G, Common Stock, Beneficial Ownership, Institutional Investor, Passive Investment, SEC Filing, Biotechnology, Pharmaceuticals